Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mineralys Therapeutics, Inc. ( (MLYS) ) has issued an update.
On September 2, 2025, Mineralys Therapeutics, Inc. announced an underwritten public offering of 9,803,921 shares of its common stock at $25.50 per share, with expected net proceeds of approximately $234.7 million. The offering, which is expected to close on September 4, 2025, aims to fund the clinical development of lorundrostat and other corporate purposes, enhancing Mineralys’ financial position and supporting its focus on hypertension-related therapies.
The most recent analyst rating on (MLYS) stock is a Hold with a $26.00 price target. To see the full list of analyst forecasts on Mineralys Therapeutics, Inc. stock, see the MLYS Stock Forecast page.
Spark’s Take on MLYS Stock
According to Spark, TipRanks’ AI Analyst, MLYS is a Neutral.
Mineralys Therapeutics shows promise with positive clinical trial results and a strong cash position, but faces challenges with continuous losses and negative cash flows. Technical analysis suggests short-term momentum, while valuation remains a concern due to lack of revenue. The earnings call highlighted upcoming milestones that could enhance future prospects.
To see Spark’s full report on MLYS stock, click here.
More about Mineralys Therapeutics, Inc.
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease and obstructive sleep apnea. Its initial product candidate, lorundrostat, is an orally administered, highly selective aldosterone synthase inhibitor.
Average Trading Volume: 1,068,747
Technical Sentiment Signal: Buy
Current Market Cap: $1.03B
See more data about MLYS stock on TipRanks’ Stock Analysis page.